Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2009-10-12
2010-11-23
Bowman, Amy (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024500
Reexamination Certificate
active
07838507
ABSTRACT:
RNA interference is provided for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression. Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and wound healing. Such disorders are treated by administering interfering RNAs of the present invention.
REFERENCES:
patent: 5585270 (1996-12-01), Grotendorst et al.
patent: 5734039 (1998-03-01), Calabretta et al.
patent: 6069006 (2000-05-01), Grotendorst et al.
patent: 6326193 (2001-12-01), Liu et al.
patent: 6348329 (2002-02-01), Schmidt et al.
patent: 6358741 (2002-03-01), Schmidt et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 2002/0086356 (2002-07-01), Tuschl et al.
patent: 2002/0114784 (2002-08-01), Li et al.
patent: 2002/0162126 (2002-10-01), Beach et al.
patent: 2003/0027783 (2003-02-01), Zernicka-Goetz et al.
patent: 2003/0153524 (2003-08-01), Hinton et al.
patent: 2004/0005319 (2004-01-01), Grotendorst et al.
patent: 2004/0053411 (2004-03-01), Cullen et al.
patent: 2004/0092450 (2004-05-01), Grotendorst et al.
patent: 2004/0147475 (2004-07-01), Li et al.
patent: 2004/0175732 (2004-09-01), Rana
patent: 2004/0203145 (2004-10-01), Zamore et al.
patent: 2004/0235031 (2004-11-01), Schultz et al.
patent: 2359180 (2001-07-01), None
patent: WO 94/01550 (1994-01-01), None
patent: WO 00/44895 (2000-08-01), None
patent: WO 01/36646 (2001-05-01), None
patent: WO 01/68836 (2001-09-01), None
patent: WO 02/044321 (2002-06-01), None
patent: WO 03/049773 (2003-06-01), None
patent: WO 03/092584 (2003-11-01), None
patent: WO 2004/022782 (2004-03-01), None
patent: WO 2004/031237 (2004-04-01), None
patent: WO 2004/065546 (2004-08-01), None
patent: WO 2005/079815 (2005-09-01), None
patent: WO 2005/083083 (2005-09-01), None
Tuschl et al., The siRNA user guide, Aug. 26, 2001 (on-line), retrieved Jan. 31, 2002, Max Planck Institute for Biophysical Chemistry, pp. 1, 3 and 5, http://www.mpibpc.gwdg.de/abteilungen/100/105/siRNAuserguide.pdf.
Holen et al., Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor, 2002, Nucleic Acids Research, vol. 30, No. 8, pp. 1757-1766.
Luo et al., The gene-silencing efficiency of siRNA is strongly dependent on the local structure of mRNA at the targeted region, 2004, Biochemical and Biophysical Research Communications, 318, pp. 303-310.
Elbashir et al., Functional anatomy of siRNAs for mediating efficienct RNAi in Drosophila melanogaster embryo lysate, 2001, The EMBO Journal, vol. 20, No. 23, pp. 6877-6888.
Hammond et al., Post-Transcriptional Gene Silencing by Double-Stranded RNA, 2001, Nature Reviews, Genetics, vol. 2, pp. 110-119.
Zhang et al., Targeted Gene Silencing by Small Interfering RNA-Based Knock-Down Technology, 2004, Current Pharmaceutical Biotechnology, vol. 5, p. 1-7.
Mahato et al., Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA, Jan. 2005, Expert Opinion on Drug Delivery, vol. 2, No. 1, pp. 3-28.
Scherer et al., Approaches for the sequence-specific knockdown of mRNA, 2003, Nat. Biotechnol., 21(12), pp. 1457-1465.
Ambion, Inc.; “Matched SIRNAs and Assays,” Technotes, vol. 11, No. 4, www.ambion.com/techlib/tn/14/4..html; date unknown, ISR states Jul. 2004.
Croci S. et al.; “Inhibition of Connective Tissue Growth Factor (CTGF/CCN2) Expression Decreases The Survival and Myogenic Differentiation of Human Rhabdomyosarcoma Cells,”Cancer Research, pp. 1730-1736, vol. 64, No. 5, Mar. 2004.
Fuchshofer R. et al.; “Transforming Growth Factor-Beta2 Modulated Extracellular Matrix Component Expression in Cultured Human Optic Nerve Head Astrocytes.”Investigative Ophthalmology&Visual Science, pp. 568-578, vol. 46, No. 2, Feb. 2005.
Shepard et al.; “Importance of Quantitative PCR Primer Location for Short Interfering RNA Efficacy Determination,”Analytical Biochemistry, pp. 287-288, vol. 344, No. 2, Jun. 21, 2005 (online) and Sep. 15, 2005, Academic Press, New York NY.
Wang et al.; “Connective Tissue Growth Factor SIRNA Modulates mRNA Levels For a Subset of Molecules in Normal and TGF-Beta1-Stimulated Porcine Skin Fibroblasts,”Wound Repair and Regeneration, pp. 205-216, vol. 12, No. 2, Mar. 2004.
Welge-Lussen et al.; “CTGF is the Fibrogenic Mediator of TGF-beta in PVR Disease,”102. Jahrestagung der Dog Duetsche Ophthalmologische Gesellschaft e. V., 23 bis, Sep. 26, 2004, Berlin, Germany, www.egms.de/en/meetings/dog2004/04dog159.html.
PCT International Search Report, PCT/US2005/046064, mailed May 26, 2006.
PCT Written Opinion of the International Searching Authority, PCT/US2005/046064, mailed May 28, 2006.
Ambros, “The functions of animal microRNAs”,Nature, pp. 350-355, vol. 431, Sep. 16, 2004, © 2004, Nature Publishing Group.
Bartel, “MicroRNAs: Genomics, Biogenesis, Mechanism, and Function”,Cell, pp. 281-297, vol. 116, Jan. 23, 2004, © 2004, Cell Press.
Croci, et al, “Inhibition of Connective Tissue Growth Factor (CTGF/CCN2) Expression Decreases the Survival and Myogenic Differentiation of Human Rhabdomyosarcoma Cells”, pp. 1730-1736, vol. 64, Cancer Research, Mar. 1, 2004.
Dorsett, et al., “SiRNAs: Applications in Functional Genomics and Potential as Therapeutics”,Nature, pp. 318-329, vol. 3, Apr. 2004, © 2004, Nature Publishing Group.
Elbashir, et el., “Duplexes of 21—nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells”,Letters to Nature, pp. 494-498, vol. 411, May 24, 2001, © 2001, McMillan Magazines Ltd.
Elbashir, et al., “Functional Anatomy of siRNAs for Mediating Efficient RNAi inDrosophila melanogasterembryo lysate”,The EMBO Journal, pp. 6877-6888, vol. 20, No. 23, 2001, © European Molecular Biology Organization.
Elbashir, et al., “RNA interference is mediated by 21- and 22-nucleotide RNAs”,Genes&Development, pp. 188-200, vol. 15, © 2001 Cold Spring Harbor Laboratory Press, ISSN 0890-9369/01.
Elbashir, at at., “Analysis of gene function in somatic mammalian cells using small interfering RNAs”,Methods, pp. 199-213, vol. 26, © 2002 Elsevier Science (USA).
Hannon, et al. “Unlocking the potential of the human genome with RNA interference”,Nature, pp. 371-378. vol. 431, Sep. 16, 2004, © 2004, Nature Publishing Group.
He, et al., “MicroRNAs: Small RNAs With A Big Role In Gene Regulation”,Reviews, pp. 522-531, vol. 5, Jul. 2004, www.nature.com/reviews/genetics.
Kawasaki, et al, “Induction of DNA methylation and gene silencing by short Interfering RNAs in human cells”,Nature, pp. 211-217, vol. 431, Sep. 9, 2004, © 2004, Nature Publishing Group.
Lim, et at, “Vertebrate MicroRNA Genes”,Science, pp. 1540, vol. 299, Mar. 7, 2003, www.sciencemag.org.
Liu, et el., “Argonaute2 is the Catalytic Engine of Mammalian RNAi”,Science, pp. 1437-1441, vol. 305, Sep. 3, 2004, www.sciencemag.org.
Morris, et al., “Small Interfering RNA-Induced Transcriptional Gene Silencing in Human Cells”,Science, pp. 1289-1292, vol. 305, Aug. 27, 2004, www.sciencemag.org.
NCBI Sequence NM—001901, “Homo sapiens connective tissue growth factor (CTGF), mRNA.”pp. 1, 11, 12 & 13, http://www.ncbi.nlm.nih.gov, printed Nov. 11, 2005.
NCBI Sequence AK092280, “Homo sapiens cDNA FLJ34961 fis, clone NTONG2003839, highly similar to Connective Tissue Growth Factor Precursor.” pp. 1.3, http://www.ncbi.nlm.nih.gov, printed Nov. 11, 2005.
NCBI Sequence AK125220, “Homo sapiens cDNA FLJ43230 fis, clone HCHON2001269, highly similar to Connective Tissue Growth Factor Precursor.” pp. 1-3, http://www.ncbi.nlm.nih.gov, printed Nov. 11, 2005.
NCBI Sequence AY395801, “Homo sapiens connective tissue growth factor (CTGF) mRNA, complete cds.” pp. 1-2; http://www.ncbi.nlm.nih.gov, pr
Pang Iok-Hou
Shepard Allan R.
Alcon Inc.
Bowman Amy
Derry Jason J.
LandOfFree
RNAi inhibition of CTGF for treatment of ocular disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with RNAi inhibition of CTGF for treatment of ocular disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNAi inhibition of CTGF for treatment of ocular disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4252304